Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
- Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and long-term efficacy of nemolizumab in prurigo nodularis and atopic dermatitis, respectively
- Galderma will also host a symposium and industry hub session for healthcare professionals on the impact of itch in prurigo nodularis and atopic dermatitis to further educate on these serious conditions
- Three additional industry hub sessions will explore Galderma’s latest research from across the full dermatology spectrum, including on sensitive skin - featuring updates from the Global Sensitive Skincare Faculty - as well as on new skin quality and holistic acne management tools
- In total, Galderma will present 30 abstracts at the congress, reinforcing its leadership and commitment to advancing dermatology for every skin story
ZUG, Switzerland -- (BUSINESS WIRE) --
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024, reinforcing its commitment to advancing dermatology for every skin story. In addition to presenting 30 abstracts with data on prurigo nodularis, atopic dermatitis, sensitive skin and acne, Galderma will host a series of events dedicated to addressing the real needs of patients and connecting with the dermatology community, including a symposium and several industry hub sessions and Meet the Experts sessions at the Galderma booth.
“EADV is such an important opportunity for us to connect with the community so we can share updates and facilitate discussions that will accelerate science in dermatology. This year, our congress program, including the presentation of new data on nemolizumab in both prurigo nodularis and atopic dermatitis, underscores our leading position in the field and highlights the power of our unique, integrated dermatology strategy.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
Deep diving on nemolizumab data in prurigo nodularis and atopic dermatitis
Galderma will be presenting nine abstracts on its monoclonal antibody nemolizumab. These include three late-breaking presentations, one on its durability in prurigo nodularis on Wednesday 25 September at 2:15 – 2:30 pm CET and two on its long-term efficacy and transcriptomics data in atopic dermatitis on Wednesday 25 September at 3 – 3:15 pm CET and 4:30 – 4:45 pm CET, respectively. Additional data will be presented on nemolizumab’s speed of onset in prurigo nodularis, immunogenicity profile, and dosing.
The symposium and industry hub session for healthcare professionals will also explore the unmet needs in prurigo nodularis and atopic dermatitis, including the impact of itch, reinforcing Galderma’s ongoing commitment to addressing the most burdensome symptom of both diseases.1,2 The industry hub session, titled “From neglect to necessity: Elevating itch monitoring in atopic dermatitis and prurigo nodularis” will be held on Thursday, September 26, 4:15-5:00 PM CET (Hub 1.09) and hosted by Prof. Jonathan Silverberg, Prof. Shawn Kwatra, and Prof. Martin Metz. The symposium, titled "Shifting the paradigm in the management of atopic dermatitis and prurigo nodularis: Expert insights into the unmet need for itch control” will take place on Friday, September 27, 1:00-2:00 PM CET (Room 7.2). It will be chaired by Prof. Diamant Thaçi, featuring guest speakers Prof. Sonja Ständer, Dr. Sarina Elmariah, and Dr. Andrew Pink.
Showcasing best-in-class science across the full spectrum of dermatology
Galderma will also host an event to share updates from its Global Sensitive Skincare Faculty (GSSF), a first-of-its-kind global community of experts dedicated to creating a better life for people with sensitive skin. Since its inception in 2022, the GSSF has promoted the advancement of sensitive skin science, establishing sensitive skin as a distinct and complex condition. During this session, chaired by Prof. Giovanni Pellacani, experts will share data and trends from the most extensive global epidemiological survey ever conducted - with more than 16,000 subjects - and discuss how this research can be applied in clinical practice. The industry hub session titled “Decoding sensitive skin: Revolutionary and unexpected findings from the broadest worldwide profiling survey” will take place on Thursday, September 26, 2:15-3:00 PM CET (Hub 1.07).
An industry hub session titled “New Skin Quality Assessment Scale – Looking Beyond the Disease” will delve into a new tool Galderma has developed to accurately assess and improve skin quality. The event will take place on Thursday, September 26, 3:15-4:00 PM CET (Hub 1.08).
Finally, attendees interested in acne management can learn more during the dedicated industry hub session “OneAcne: A holistic management approach to improve treatment outcomes in acne, acne sequelae and skin quality”, which will be taking place on Friday, September 27, 3:15-4:00 PM CET (Hub 1.14). Participants will be invited to explore Galderma’s integrated approach in acne management and its unique portfolio of tools from across the dermatology spectrum combined to manage the individual needs of acne patients, from acne prone skin, through breakouts, to scarring.
More details on Galderma’s scientific presentations at EADV can be found here.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
References:
- Pereira MP, et al. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. J Eur Acad Dermatol Venereol. 2018;32(12):2224-2229. doi:10.1111/jdv.15107
Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347. doi:10.1016/j.anai.2018.07.006
- ins营销新手也能搞定:Instagram群发引流,零基础也能迅速引流爆粉!
- LMN 2024世界激光制造大会于大族激光盛大启幕,共探激光技术新趋势
- 攀派潮汕牛肉火锅:传承与创新,绽放美食新光彩
- 《徐怀钰2024倒数3秒巡回演唱会》北京站正式开票,共赴9年之约
- 【南昌建设医院】是私人医院吗?看病综合实力怎么样?
- 重拳反诈:南京移动协助警方捣毁电诈团伙窝点
- 「行则将至 乘风起航」港大ICB 2024年秋季校内工作坊圆满落幕
- Boomi通过新的API控制平面增强API管理产品,以实现集中式发现、管理和治理
- Bitget Launches P2P Security Layer 'Shield' to Ensure Safety and Mitigate Users' Loss
- Andersen Global在哥伦比亚创办成员事务所
- Christie's International Real Estate Enters Singapore as Luxury Brand Continues Expansion in So
- 康悦到家——养生理疗技师可以预约上门去服务,真是便利到家啦
- 中信银行西安分行联合社区开设便民服务驿站
- 新意网获颁联合国可持续发展目标香港成就奖 2024 — 优异表现奖
- 仲利国际再获殊荣!助力长宁区区域经济回升向好
- 暖心沪伴共赴团圆 沪上阿姨天津送出新春公益大礼包
- 以品质服务点亮万家灯火,恒洁连续五年“春节服务不打烊”
- Conformation-X Therapeutics 脱颖而出,获得超过 1350 万美元的资金以推动其创新的免疫肿瘤学产品线
- 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系
- MoneyHero Group Announces Year of Innovation and Growth for its Market-Leading Insurance Vertical
- 姜育恒“人生的路”巡回演唱会深圳站为爱而唱 金曲连唱感动迭起
- 浙江干冰销售电销售干冰
- 成都风生水起文化传播有限公司——企业为什么需要管理咨询?
- YAMASHITA 股份有限公司在上海成立中国康养投资总部——山下(上海)养老服务有限公司
- 中国男人终于有了自己的节日一一首届"中华父亲节"成功举办
- SU7“人、车、家”合一的生态互联与路凯智行“懂车、懂矿、懂算法”的不谋而合
- 平安养老险安徽分公司:普惠金融进企业,暖心服务“零距离”
- 超凡实力,亲眼见证!金领冠珍护‘超凡宝宝童乐汇’重庆站盛大启幕,精彩不容错过!
- 商忆莎《云雾女孩》正在热映 被称最具故事感的女演员
- Irdeto与Bitmovin合作,提供先进的安全低延迟流媒体和卓越的用户体验
推荐
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯